| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Introgen Therapeutics, Inc. |
| 301 Congress Avenue, Suite 1850, Austin, TX 78701 * (512) 708-9310 |
| Business Description | The company is a leading developer of gene therapy products for the treatment of cancer. We are capitalizing on the significant advances in the understanding of the human genome and the role that genetic function plays in the development of cancer. |
| Offering Information Company has | |||
| Trading As | INGN (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 2/17/00 |
| Domestic Shares Offered | 4,000,000 | Offer Date | 10/11/00 |
| Foreign Shares Offered | 0 | Filing Range | $12.00 - $14.00 |
| Company Shares | 4,000,000 | Offer Price | $8.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.560 |
| Gross Proceeds | $32,000,000 | Selling | $0.320 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | - - | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| SG Cowen | Lead Manager | (212) 495-6000 |
| Prudential Vector Healthcare | Co-manager | (800) 546-1231 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 6/30/95 | 6/30/96 | 6/30/97 | 6/30/98 | 6/30/99 | 12/31/98 | 12/31/99 |
| Revenues | 2.664 | 10.449 | 12.052 | 8.606 | 6.714 | 3.974 | 3.916 |
| Income from Oper. | -1.332 | -1.543 | -3.537 | -2.804 | -3.321 | -1.428 | -3.955 |
| Net Income | -1.225 | -1.332 | -3.116 | -2.015 | -2.646 | -1.019 | -3.747 |
| E.P.S | -0.500 | -0.550 | -1.280 | -0.820 | -1.060 | -0.410 | -1.480 |
| Revenue Growth (%) | 292.23 | 15.34 | -28.59 | -21.985 | -1.46 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -1.95 | -2.43 | -3.74 | ||||
| Cash Flow - Inv. | -5.39 | 3.15 | 1.18 | ||||
| Cash Flow - Fin. | 8.30 | 0.02 | 2.81 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 26.32 | Current Assets | 14.79 | Current Ratio | 8.19 |
| Total Liab. | 9.89 | Current Liab. | 1.81 | Debt Ratio | 37.59% |
| Total Equity | 16.42 | Working Cap. | 12.98 | Debt to Equity Ratio | 0.60 |
| Cash | 2.40 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to conduct research and development, including clinical trials, advance our process development and manufacturing capabilities and initiate product marketing and commercialization programs, and for general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Bank's Law Firm | Shearman & Sterling |
| Registrar/Transfer Agent | Norwest Bank of Minnesota |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Rhone-Poulenc Rorer International (Holdings) Inc. | 24.10 | |
| The Board of Regents of The University of Texas System | 7.30 | |
| Nomura International PLC | 5.80 | |
| Note: represents ownership of 5% or more prior to the offering. | ||